NCT05399498CompletedPhase 2
Psilocybin in Co-occuring Major Depressive Disorder and Borderline Personality Disorder
An Open Label Study of Single-Dose Psilocybin for Major Depressive Disorder With Co-occurring Borderline Personality Disorder
Source: ClinicalTrials.gov · Last updated 29 Oct 2026
Brief summary (registry, in English)
The primary objective of the study is to evaluate the safety and efficacy of psilocybin in adults with major depressive disorder (MDD) and borderline personality disorder (BPD).
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- First submitted
- 26 May 2022
- Start date
- 1 Nov 2023
- Primary completion date
- 1 Dec 2025
- Lead sponsor
- University of Chicago
- Diseases
- Depression
- NCT number
- NCT05399498
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 10
- From 1 Nov 2023 to the primary completion date, 1 Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Unstable medical illness based on history or clinically significant abnormalities on baseline physical examination
- Current or past history of bipolar I disorder, schizophrenia, or schizoaffective disorder
- Active substance use disorder
Other
- Current pregnancy or lactation, or inadequate contraception in women of childbearing potential
- Illegal substance use based on urine toxicology screening (except cannabis use)
Who the study is looking for
- Age 18-65
- Diagnosed with current major depressive disorder (MDD)
- Montgomery-Asberg Depression Rating Scale (MADRS) score of \> 20
- Diagnosed with borderline personality disorder (BPD)
- Borderline Personality Disorder Symptom Assessment Scale (BPD-SAS) score of \> 20
- Ability to understand and sign the consent form
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Chicago Coordinator of this site? Confirm its status | Chicago | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.